Health News Archive - February 24, 2010
AMSTERDAM, February 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009. Highlights - Glybera(R) Marketing Authorisation Application submitted to European Medicines Agency (EMA, formerly known as EMEA); - EMA commenced formal review of Glybera(R) dossier on January 20, 2010; - EMA grants orphan drug designation for AMT's Acute Intermittent Porphyria ("AIP") program; - EMA grants orphan drug designation for AMT's Duchenne Muscular Dystrophy ("DMD") program; - SenterNovem awards EUR 4 million investment credit for the development of AMT's DMD program; - Raised EUR 5 million convertible loan notes, which convert into ordinary shares at EUR 3.91 per share; - New management team. Jorn Aldag, Chief Executive Officer of AMT, commented: "In 2009 we announced a rebalancing of our st
Topline Findings from a Survey of More than 250 Dentists 30,000+ Dental Professionals Converge in Chicago February 25-27 CHICAGO, Feb.
CASE NOT CLOSED ON GOVERNMENT VACCINE SAFETY CLAIMS WASHINGTON, Feb.
ALISO VIEJO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Clarient, Inc.
CARLSBAD, Calif., Feb.
PARIS, February 24, 2010 /PRNewswire/ -- - "Patients and Researchers: Partners for Life!" - 28 February Marks the Third Rare Disease Day For this annual event hundreds of patient groups and their partners organise activities to raise awareness on rare diseases and the 30 million people affected by them in Europe. Rare Disease Day was launched and is coordinated by the European Organisation for Rare Diseases - EURORDIS (http://www.eurordis.org), a federation representing more than 400 patient organisations in 42 countries. The campaign involves rare disease national alliances and patient groups in 40 countries, in the EU as well as in the USA, Canada, Argentina, Australia, New Zealand, Japan, China and Taiwan, amongst others. The European Union considers a disease as rare when it affects less than 1 in 2,000 citizens.
LITTLE ROCK, Ark., Feb. 24 /PRNewswire/ -- For 34 years, Dr. James Arkins has been caring for the health needs of thousands of families in Northwest Arkansas. But thanks to a gift by The Walton Family Foundation, Dr.
WOODCLIFF LAKE, N.J., Feb. 24 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc.
CAMBRIDGE, Massachusetts, February 24, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. Shire filed a BLA for REPLAGAL in December 2009.
OMAHA, Neb., Feb. 24 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today that it has licensed on an exclusive U.S.